Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.

Wataru MunakataYukari ShirasugiKensei TobinaiMakoto OnizukaShinichi MakitaRikio SuzukiDai MaruyamaHidetsugu KawaiKoji IzutsuTadashi NakanishiSari ShibaSeichiro HojoKiyoshi Ando

Published in: Cancer science (2021)

Tazemetostat at 800 mg BID showed an acceptable safety profile and promising antitumor activity in Japanese patients with relapsed or refractory B-NHL.

Keyphrases

diffuse large b cell lymphoma
acute lymphoblastic leukemia
acute myeloid leukemia
multiple myeloma
hodgkin lymphoma
open label